As previously reported, Guggenheim analyst Eddie Hickman downgraded Iveric bio (ISEE) to Neutral from Buy with a price target of $40, down from $43, after Astellas Pharma (ALPMY) agreed to acquire Iveric for $40 per share in cash. The firm likes the price, which supports its belief in avacincaptad pegol’s best-in-class profile, and doesn’t expect other bidders, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ISEE:
- Optics of Iveric deal may pressure Apellis near-term, says Baird
- Iveric bio downgraded to Neutral from Outperform at Wedbush
- Apellis should be bought on selloff from Iveric deal, says Citi
- Iveric bio downgraded to Neutral from Buy at Guggenheim
- Iveric Bio (NASDAQ:ISEE) Sold for $5.9B
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue